Breaking News

GSK Halts HSV Vaccine Development After Phase II Failure

The vaccine candidate did not achieve its primary goal in the TH HSV REC-003 trial.

Author Image

By: Charlie Sternberg

Associate Editor

GlaxoSmithKline plc (GSK) announced today that its early-stage herpes simplex virus (HSV) vaccine candidate, GSK3943104, has failed to meet the primary efficacy objective in a phase II clinical trial. As a result, the company will not be moving forward with phase III development for this particular vaccine.   The decision comes after a thorough analysis of data from the TH HSV REC-003 trial, a combined phase I/II proof-of-concept study designed to assess the potential clinical efficacy of the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters